Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 41.00 0.00
Piotroski F-Score
— — — 4 1 2 5 7 3
Altman Z-Score
— — 6.15 33.28 13.21 7.59 5.56 6.74 6.70
P/S ratio
1.70 1.70 5.69 20.29 11.45 4.33 2.68 2.23 3.28
Altman Z″-Score (non-manufacturers)
— (6.93) 7.12 24.00 11.93 10.19 7.63 9.07 6.15
P/FCF ratio
0.00 0.00 48.54 248.40 0.00 0.00 0.00 20.25 39.74
Beneish M-Score
— — (2.01) (2.38) 11.61 (2.41) (2.37) (2.58) (3.49)
P/Operating CF
95.59 95.59 65.66 (2,956.01) (387.49) (98.92) 31.67 30.38 41.87
P/B ratio
0.00 0.00 3.47 3.06 2.62 1.49 1.50 1.62 2.39
Price to Tangible BV
0.00 0.00 3.47 3.06 3.34 2.18 2.15 2.12 3.04
EV/Sales
1.96 1.96 4.27 14.11 8.04 2.54 1.64 1.38 2.44
EV/EBITDA
0.00 0.00 23.03 0.00 0.00 0.00 0.00 25.44 0.00
EV/Operating CF
(16.06) (16.06) 31.55 89.58 (39.83) (8.36) (63.99) 7.05 13.03
EV/FCF
(13.90) (13.90) 36.41 172.70 (33.67) (7.39) (18.72) 12.51 29.55
Quick Ratio
1.12 2.46 7.42 20.24 13.94 7.81 5.90 6.97 4.99
Current Ratio
1.28 2.69 7.63 20.58 14.21 8.09 6.20 7.29 5.26
Net Debt/EBITDA
(1.78) (6.79) (7.67) 78.35 8.77 3.85 3.98 (15.73) 46.20
Debt/Assets
0.00% 109.35% 20.98% 0.00% 1.75% 2.98% 0.00% 1.95% 1.79%
Debt/Equity
(1.27) (0.43) 0.30 0.00 0.02 0.03 0.00 0.02 0.02
Asset Turnover
0.85 2.03 0.73 0.22 0.21 0.30 0.49 0.67 0.62
Operating CF/Net income
0.80 1.21 2.35 (0.96) 0.61 0.62 0.10 3.56 (2.66)
Capex/Depreciation
0.00 (0.31) (0.41) (3.62) (1.02) (0.59) (1.99) (3.04) (0.98)
Interest Coverage
(13.01) (1.69) 1.60 (2.48) (40,079.00) (4,285.59) (6,179.73) 15.03 (497.79)
ROE
28.65% 19.02% 20.95% (4.11%) (7.56%) (16.56%) (14.54%) 4.31% (5.21%)
ROA
(95.00%) (90.72%) 4.21% (3.68%) (6.94%) (14.76%) (12.76%) 3.71% (4.35%)
ROIC
0.00% 0.00% 40.21% (70.02%) (27.78%) (29.60%) (28.67%) 3.13% (14.72%)
Return on Tangible Assets
(521.83%) (78.67%) 2.89% (2.47%) (9.25%) (24.82%) (21.02%) 5.04% (6.20%)
Average Days of Receivables
123.46 193.67 103.09 74.34 67.05 62.53 63.61 56.30 46.00
Research and Development Expense of Revenue
32.21% 21.30% 14.24% 21.16% 31.51% 32.77% 24.40% 15.67% 15.06%
Selling, General and Administrative Expense of Revenue
110.37% 72.29% 57.54% 76.83% 92.19% 104.35% 81.97% 60.24% 66.62%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.19 0.28 0.26 0.20 0.17
Share Based Compensation of Revenue
0.00% 1.29% 2.41% 13.26% 23.11% 26.50% 23.30% 15.15% 13.33%
Graham Net Nets
(1.19) (1.19) 0.28 0.32 0.28 0.41 0.40 0.38 0.22
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.49 0.00
Earnings Yield
(24.42%) (24.42%) (3.52%) (0.76%) (2.89%) (11.33%) (9.84%) 2.44% (2.16%)
Free Cash Flow Yield
(8.33%) (8.33%) 2.06% 0.40% (2.08%) (7.93%) (3.27%) 4.94% 2.52%
Revenue per Share
0.83 11.95 6.04 3.31 3.74 5.26 8.20 11.96 11.88
Operating CF per Share
(0.73) (6.45) 0.82 0.52 (0.76) (1.60) (0.21) 2.34 2.22
Capex per Share
0.00 (0.15) (0.11) (0.25) (0.14) (0.21) (0.51) (1.02) (1.24)
Free Cash Flow per Share
(0.73) (6.60) 0.71 0.27 (0.89) (1.81) (0.72) 1.32 0.98
Cash per Share
0.07 2.35 11.52 21.65 13.11 9.93 9.07 10.55 10.33
Shareholders Equity per Share
(0.95) (29.68) 9.92 21.96 16.38 15.32 14.60 16.41 16.24
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.95) (29.68) 9.92 21.96 16.38 15.32 14.60 16.41 16.24
Free Cash Flow
(12.23) (12.57) 6.08 5.12 (22.46) (47.09) (19.23) 36.56 28.37
Working Capital
1.46 11.39 101.39 408.72 328.86 256.16 247.97 310.76 292.42
Capital Expenditures
(0.49) (0.28) (0.94) (4.75) (3.47) (5.44) (13.61) (28.31) (35.98)
Net Current Asset Value
(18.91) (60.84) 82.05 405.96 302.91 244.11 233.56 284.75 253.41
EV/EBIT
0.00 0.00 30.20 0.00 0.00 0.00 0.00 52.76 0.00
Capex to Sales
0.00 0.01 0.02 0.08 0.04 0.04 0.06 0.09 0.10
Price to Operating Income
0.00 0.00 40.26 0.00 0.00 0.00 0.00 85.38 0.00
Other line items
Depreciation/Fixed assets
0.21 0.58 1.11 0.18 0.36 0.64 0.27 0.18 0.38
Cash ROIC
(220.68%) 45.57% 2.91% 0.62% (3.00%) (7.02%) (3.03%) 4.81% 3.63%
Accounts Receivable Turnover
1.64 2.72 3.88 4.57 6.26 6.72 7.12 7.42 7.28
Accounts Payable Turnover
3.93 4.13 4.41 4.89 6.81 8.80 6.00 7.01 5.55
Inventory Turnover
8.50 8.93 6.90 5.61 7.47 10.67 7.55 7.49 7.73
Average Days of Payables
80.81 99.98 93.12 79.07 58.73 53.95 83.32 41.84 96.15
Days of Inventory on Hand
22.04 60.78 61.77 83.55 46.62 45.38 64.44 49.32 52.69
Average Receivables
8.37 8.37 13.37 13.70 15.02 20.38 30.89 44.76 47.30
Average Payables
1.28 1.28 1.66 1.98 2.32 3.64 7.50 8.58 12.81
Average Inventory
0.59 0.59 1.06 1.73 2.12 3.00 5.96 8.04 9.19
Average Assets
16.11 11.20 71.08 279.54 450.95 454.95 450.33 492.29 554.90
Average Common Equity
(53.44) (53.44) 14.27 250.40 413.72 405.45 395.21 423.55 463.35

Fold the line items

Columns are period end dates